Home > Publications Database > Omega-3 fatty acid diglyceride emulsions as a novel injectable acute therapeutic in neonatal hypoxic-ischemic brain injury. > print

001     269866
005     20240808164406.0
024 7 _ |a pmc:PMC11156760
|2 pmc
024 7 _ |a 10.1016/j.biopha.2024.116749
|2 doi
024 7 _ |a pmid:38761420
|2 pmid
024 7 _ |a 0300-0893
|2 ISSN
024 7 _ |a 0753-3322
|2 ISSN
024 7 _ |a 1950-6007
|2 ISSN
024 7 _ |a altmetric:164274238
|2 altmetric
037 _ _ |a DZNE-2024-00692
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zirpoli, Hylde
|b 0
245 _ _ |a Omega-3 fatty acid diglyceride emulsions as a novel injectable acute therapeutic in neonatal hypoxic-ischemic brain injury.
260 _ _ |a Paris [u.a.]
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1719234921_2991
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 0753-3322 not unique: **2 hits**.
520 _ _ |a Hypoxic-ischemic encephalopathy (HIE), resulting from a lack of blood flow and oxygen before or during newborn delivery, is a leading cause of cerebral palsy and neurological disability in children. Therapeutic hypothermia (TH), the current standard of care in HIE, is only beneficial in 1 of 7-8 cases. Therefore, there is a critical need for more efficient treatments. We have previously reported that omega-3 (n-3) fatty acids (FA) carried by triglyceride (TG) lipid emulsions provide neuroprotection after experimental hypoxic-ischemic (HI) injury in neonatal mice. Herein, we propose a novel acute therapeutic approach using an n-3 diglyceride (DG) lipid emulsions. Importantly, n-3 DG preparations had much smaller particle size compared to commercially available or lab-made n-3 TG emulsions. We showed that n-3 DG molecules have the advantage of incorporating at substantially higher levels than n-3 TG into an in vitro model of phospholipid membranes. We also observed that n-3 DG after parenteral administration in neonatal mice reaches the bloodstream more rapidly than n-3 TG. Using neonatal HI brain injury models in mice and rats, we found that n-3 DG emulsions provide superior neuroprotection than n-3 TG emulsions or TH in decreasing brain infarct size. Additionally, we found that n-3 DGs attenuate microgliosis and astrogliosis. Thus, n-3 DG emulsions are a superior, promising, and novel therapy for treating HIE.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a diglycerides
|2 Other
650 _ 7 |a gliosis
|2 Other
650 _ 7 |a hypoxic-ischemic encephalopathy
|2 Other
650 _ 7 |a lipid emulsion
|2 Other
650 _ 7 |a neuroprotection
|2 Other
650 _ 7 |a omega-3 fatty acids
|2 Other
650 _ 7 |a Fatty Acids, Omega-3
|2 NLM Chemicals
650 _ 7 |a Emulsions
|2 NLM Chemicals
650 _ 7 |a Neuroprotective Agents
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Hypoxia-Ischemia, Brain: drug therapy
|2 MeSH
650 _ 2 |a Animals, Newborn
|2 MeSH
650 _ 2 |a Fatty Acids, Omega-3: administration & dosage
|2 MeSH
650 _ 2 |a Fatty Acids, Omega-3: pharmacology
|2 MeSH
650 _ 2 |a Emulsions
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Neuroprotective Agents: administration & dosage
|2 MeSH
650 _ 2 |a Neuroprotective Agents: pharmacology
|2 MeSH
650 _ 2 |a Rats
|2 MeSH
650 _ 2 |a Rats, Sprague-Dawley
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Brain: drug effects
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
700 1 _ |a Bernis, Maria Eugenia
|0 P:(DE-2719)2810557
|b 1
|u dzne
700 1 _ |a Sabir, Hemmen
|0 P:(DE-2719)9000732
|b 2
|u dzne
700 1 _ |a Manual Kollareth, Denny Joseph
|b 3
700 1 _ |a Hamilton, James A
|b 4
700 1 _ |a Huang, Nasi
|b 5
700 1 _ |a Ng, Jesse
|b 6
700 1 _ |a Sosunov, Sergey A
|b 7
700 1 _ |a Gaebler, Ben
|b 8
700 1 _ |a Ten, Vadim S
|b 9
700 1 _ |a Deckelbaum, Richard J
|b 10
773 _ _ |a 10.1016/j.biopha.2024.116749
|g Vol. 175, p. 116749 -
|0 PERI:(DE-600)392415-4
|p 116749
|t Biomedicine & pharmacotherapy
|v 175
|y 2024
|x 0300-0893
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/269866/files/DZNE-2024-00692.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/269866/files/DZNE-2024-00692.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:269866
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810557
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000732
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BIOMED PHARMACOTHER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 1 _ |0 I:(DE-2719)5000032
|k AG Sabir
|l Neonatal Neuroscience
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000032
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21